普門科技(688389.SH):聲治療儀(超聲V拉美)自6月份上市以來銷售情況較好
格隆匯9月5日丨普門科技(688389.SH)近期接受特定對象調研時,有投資者問:醫美業務的團隊、渠道、銷售、產品等整體情況?
答:自去年10月份公司皮膚醫美業務獨立以來,皮膚醫美專業營銷運營團隊得以快速建設和成長,目前團隊成員基本可以覆蓋全國各省市地區。渠道端方面,目前公司全國渠道簽約60餘家,廠家與渠道各司其責,共同配合加快皮膚醫美市場客户推廣和開發。皮膚醫美產品主要佈局為醫美能量產品,包括激光、超聲、衝擊波等。超聲治療儀(超聲V拉美)自6月份上市以來,產品性能受到市場認可,銷售情況較好。超聲治療儀產品與公司去年推出的體外衝擊波治療儀(冷拉提)產品形成抗衰組合,提升了公司特色能量產品的競爭力,也帶動了基礎醫美產品的銷售。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.